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Abstract: The use of proper cells for bone tissue engineering remains a major challenge worldwide.
Cells play a pivotal role in the repair and regeneration of the bone tissue in vitro and in vivo.
Currently, a large number of differentiated (somatic) and undifferentiated (stem) cells have been
used for bone reconstruction alone or in combination with different biomaterials and constructs
(e.g., scaffolds). Although the results of the cell transplantation without any supporting or adjuvant
material have been very effective with regard to bone healing. Recent advances in bone scaffolding are
now becoming new players affecting the osteogenic potential of cells. In the present study, we have
critically reviewed all the currently used cell sources for bone reconstruction and discussed the new
horizons that are opening up in the context of cell-based bone tissue engineering strategies.
Keywords: bone tissue engineering; somatic cells; embryonic stem cells; adult stem cells; induced
pluripotent stem cells; scaffold
1. Introduction
Bone tissue lesions are among the most common injuries of the human body, which affect the
quality of millions of people worldwide [1]. It has been estimated that the prevalence of bone lesions
requiring treatments will double during a period between 2012 and 2020 due to an aging population,
traumas, congenital genetic abnormalities, and obesity [2]. As such, the need for bone replacement
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increases dramatically worldwide and becomes a key scientific, socio-economic, and clinical challenge.
Recently, the use of tissue engineering (TE)-based strategies has appealed greatly for healing the
damaged bone tissue. The fundamentals of TE include three principles including cells, biomaterials,
and growth factors, which are necessary for generating the regenerated functional tissue [3]. Most of
the strategies applied for BTE are based on bone formation through intramembranous ossification (IO),
which commonly leads to poor vascularization and limited-area bone regeneration. Therefore, bone
regeneration via a cartilage-mediated process similar to endochondral ossification (EO) has recently
attracted greater attention in BTE, especially for long bones reconstruction, to overcome the limitations
of the IO approach [4,5].
As one of the main building blocks of TE field, cells have attracted increasing attention for in vitro
and in vivo bone regeneration due to their substantial role in the acceleration of the healing process.
For example, cells are able to improve the healing process by secreting numerous cytokines including
VEGF, HGF, bFGF, and IL-6 [6,7]. Moreover, cells are involved in the secretion of the extracellular matrix
(ECM), which provides necessary physical scaffolding for the cellular constituents as well as initiates
essential biochemical and biomechanical cues required for tissue morphogenesis, differentiation,
and homeostasis [8]. There are some well-recognized and accepted criteria to use in cells for in vivo
bone repair and regeneration including ease availability, abundance, a lack of the induced host immune
response, and incorporate the proper potential for osteogenic differentiation [9,10]. Currently, various
types of both differentiated (e.g. osteoblasts) and undifferentiated cells (embryonic, fetal, and adult
stem cells) are used for treating damaged bone tissue. It was previously well documented that
the nature and commitment of the transplanted cells significantly control the type of ossification
in vivo [11–13]. For example, Tortelli et al. showed that the activation of an endochondral ossification
process happened when they transplanted mesenchymal stem cells (MSCs)-seeded porous ceramic
scaffolds in immunocompromised mice, while transplantation of osteoblasts (OB)-seeded scaffolds led
to an intramembranous ossification [14].
Appropriate cell types are also used with a “probing function” to test the in vitro biocompatibility
of biomaterials and scaffolds for possible use in TE approaches. In fact, correct strategies for the
selection of implantable constructs for bone healing rely on the initial evaluation of biomaterials
using different bone cells, i.e., osteoblasts and osteoclasts [15]. The cell fate in vivo will be
determined by many biomaterial-related features, such as surface texture (e.g. micro-roughness
and nano-roughness [16,17]), the size of particles [18], dissolution kinetics, and release of ionic species
that may elicit specific biochemical and genetic responses in cells and tissues [19–23].
It is suggested that the biomedical scientists take measures on the cell source used for BTE
strategies to get better outcomes. These considerations can be summarized as follows: (1) the choice
between the use of autologous or allogeneic cells, (2) the availability of the desired tissue for cells
and subsequent harvesting procedure, (3) donor site morbidity, (4) the efficiency of the cell isolation
procedure and final yield of harvested cells, (5) the osteogenic and angiogenic potential of cells, (6) the
proliferation rate of cells, (7) the homogeneity of the isolated cells, (8) the phenotype stability and cell
safety after implantation, (9) the possibility of immunogenicity, and (10) the development of quality
control measures for the generation of cells and grafts [24]. Prior to the use of in vivo experiments,
the harvested cells are usually expanded in tissue culture treated (TC-treated) dishes under appropriate
cell culture conditions. This work results in a significant increase in the number of cells desired, which
may be useful for selection and their enrichment [25] (Figure 1).
In the present study, we have reviewed and summarized a large number of previously reported studies
in which different somatic and stem cells (Table 1) were used for bone tissue engineering (BTE) strategies
both in vitro and in vivo. For this aim, we collected the relevant articles from the databases of Scopus, Web
of Science (ISI), and PubMed. In addition, we present and discuss the general information of mammalian
cells including their history, isolation procedures, properties, advantages, and disadvantages regarding
BTE. The focus of the present study is to show the usability of each cell type for bone reconstructive
strategies and their pros and cons based on the evidence of the comparison in vitro and in vivo osteogenic
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potential. The conclusion on choosing the best cell source as an ideal candidate for bone tissue repair and
regeneration is tough because of the various conditions applied in experiments.
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Figure 1. The cell niche within the bone tissue. Osteoblasts, osteocytes, osteoclasts, mesenchymal 
cells, and endothelial cells of blood vessels create the niches and contribute to the maintenance and 
differentiation of hematopoietic stem cells (HSCs). With permission from Reference [26]. 
Table 1. Overview of the somatic and stem cells used in BTE applications. 
Cell Type Advantages Disadvantages 
Autologous osteoblasts 
- Lack of immune rejection 
- Low cost  
- No requirement for cell line 
development 
- Need for ex vivo expansion (a 
time-consuming procedure) 
- May be harmful 
Embryonic stem cells 
- Ability to differentiate into cells of all 
three primary germ layers (ectoderm, 
mesoderm, and endoderm) 
- Immortality 
- Ethical issues  
- The risk of tumorigenicity 
- Difficult culturing  
- Maybe immunogenic 
Fetal stem cells (AFSCs, AMSCs, 
Ch-MSCs) 
- High proliferation rate 
- Lack of ethical issues 
- Lack of tumorigenicity * 
- Immuno-privileged properties 
- Inability to differentiate into the 
cells of three germ layers 
- Lower potential regarding 
osteogenic differentiation than 
other cells 
Adult stem cells (BM-MSCs 
ASCs, WJMSCs, UCB-MSCs, EPCs, 
HUCPVCs, SMSCs, PDPCs, MD-SCs, 
Dental stem/progenitor cells) 
- Ease availability 
- Lack of ethical issues 
- Lack of tumorigenicity * 
- Immuno-privileged properties 
- The limited lifespan in vitro 
condition 
- Inability to differentiate into the 
cells of three germ layers  
Induced pluripotent stem cells (iPSCs) 
- Ability to differentiate into cells of all 
three primary germ layers  
- Elimination of immunological 
rejection 
- Lack of ethical issues 
- The risk of tumorigenicity 
- The safety issues about the 
retroviral transfection system 
* It has been reported that the proteins secreted by these cells may support tumor cells’ proliferation. 
Abbreviations: AFSCs: Amniotic fluid-derived stem cells, AMSCs: Amniotic membrane stems cells, 
Ch-MSCs: Chorion Mesenchymal Stem Cells, BM-MSCs: Bone marrow stem cells, ASCs: Adipose 
tissue-derived mesenchymal stem cells, WJMSCs: Umbilical cord Wharton’s jelly-derived 
mesenchymal stem cells, UCB-MSCs: Umbilical cord blood-derived mesenchymal stem cells, EPCs: 
Endothelial progenitor cells, HUCPVCs: Umbilical cord perivascular cells, PDPCs: 
Periosteum-derived progenitor cells, SMSCs: Synovium-derived mesenchymal stem cells, MD-SCs: 
Muscle-derived stem cells, iPSCs: Induced pluripotent stem cells. 
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Table 1. Overview of the somatic and st m cells used in BTE applications.
Cell Type Advantages Disadvantages
Autologous osteoblasts
- Lack of immune rejection
- Low cost
- No requirement for cell
line development
- Need for ex vivo expansion
(a time-consuming procedure)
- May be harmful
Embryonic stem cells
- Ability to differentiate into cells of all
three primary germ layers (ectoderm,
mesoderm, and endoderm)
- Immort lity
- Ethical issues
- The risk of tumorigenicity
- Difficult culturing
- Maybe immunogenic
Fetal stem cells (AFSCs,
AMSCs, Ch-MSCs)
- High proliferation rate
- Lack of ethical issues
- Lack of tumorigenicity *
- Immuno-privileged properties
- Inability to differentiate into
the cells of three germ layers
- Lower potential regarding
osteogenic differentiation
than other cells
Adult stem cells (BM-MSCs,
ASCs, WJMSCs, U B-MSCs,
EPCs, HUCPVCs, SMSCs,
PDPCs, MD-SCs, Dental
stem/progenitor cells)
- Ease availability
- Lack of ethical issues
- Lack of tumorigenicity *
- Immuno-privileged properties
- The limited lifespan
in vitro condition
- Inability to differentiate into
the cells of three germ layers
Induced pluripotent stem cells
(iPSCs)
- Ability to differentiate into cells of all
three primary germ layers
- Elimination of
immunological rejection
- Lack of ethical issues
- The risk of tumorigenicity
- The safety issues about the
retroviral
transfection system
* It has been reported that the proteins secreted by these cells may support tumor cells’ proliferation. Abbreviations:
AFSCs: Amniotic fluid-derived stem cells, AMSCs: Amniotic membrane stems cells, Ch-MSCs: Chorion
Mesenchymal Stem Cells, BM-MSCs: Bone marrow stem cells, ASCs: Adipose tissue-derived mesenchymal
stem cells, WJMSCs: Umbilical cord Wharton’s jelly-derived mesenchymal stem cells, UCB-MSCs: Umbilical cord
blood-derived mesenchymal stem cells, EPCs: Endothelial progenitor cells, HUCPVCs: Umbilical cord perivascular
cells, PDPCs: Periosteum-derived progenitor cells, SMSCs: Synovium-derived mesenchymal stem cells, MD-SCs:
Muscle-derived stem cells, iPSCs: Induced pluripotent stem cells.
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2. Differentiated Cells
With respect to BTE strategies, a couple of differentiated cells (i.e., osteoblasts and osteoclasts)
were used in both in vitro and in vivo experiments. One of the proposed applications of this type of
cells is related to in vitro evaluation of osteogenesis. However, it is possible to use them as cell sources
(i.e., auto-graft) for in vivo applications.
2.1. Osteoblasts
2.1.1. General Information
Within the nano-microstructure and microstructure of bone, predominant types of the cell
population include osteoblasts, osteoclasts, and osteocytes. Other cell types like endothelial and
chondrocyte cells have an essential role in the mineralization process. All these cell types contribute to
physiological, mechanical, and structural functions in bone [27]. Osteoblast lineage cells, including
osteo-progenitors, osteoblasts, and osteocytes, arise from pluripotent mesenchymal progenitor
cells [28]. In the bone, pluripotent progenitor cells undergo several major developmental stages.
The commitment of the pro-osteoblasts to osteoblastic lineage is regulated by a set of genes including
c-fos, c-myc, Ets-1, Runx2, matrix associated genes, osteoblast-specific genes, and bone remodeling
genes such as Dlx5 and osterix [29–31]. Mature osteoblasts progressively express specific markers
including type I collagen, alkaline phosphatase (ALP), osteonectin (ON), and osteocalcin (OCN) [32].
Osteoblasts are bone-forming cells present throughout vertebrate life, but their function is uppermost
during the embryonic period and growth [33]. Some mature osteoblasts may die by apoptosis while
some undergo quiescent flatten lining cells, or are surrounded in the ECM as osteocytes expressing the
Dmp1 Marker [34]. The steps involved in osteoblast differentiation are illustrated in Figure 2.
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bone tissue suggests that they may have an important role in the bone resorption and regeneration 
process [36]. Since the discovery of osteoblast cells, evidence has accumulated that they are the main 
Figure 2. Schematic representation of the different steps of osteoblast (OB) differentiation from
mesenchymal stem cells (MSC). With permission from Reference [35].
Osteoblasts were initially characterized based on their anatomical position as a continuous cell
layer that appeared on the surface part of the bone (cortical bone). Within their niche, osteoblasts are
commonly adjacent to endothelial cells. The close proximity of osteoblasts to the surface part of the
bone tissue suggests that they may have an important role in the bone resorption and regeneration
process [36]. Since the discovery of osteoblast cells, evidence has accumulated that they are the main
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contributors for the production of ECM under the regulation of systematic hormones such as the
parathyroid hormone (PTH) and estrogens [37,38]. Osteoblasts are mainly involved in the secretion of
collagenous and non-collagenous products in bone matrix, which can act as a pattern for the mineral
deposition [27].
2.1.2. Application in BTE
These fully differentiated cells have been applied for both in vitro and in vivo studies related to
bone reconstruction. The cyto-compatibility (e.g., cytotoxicity and genotoxicity) of various materials in
any format (powder, granule, and scaffold) is usually evaluated using these cells [39–41]. In addition,
the osteogenic potential of different substances is carried out on osteoblasts in vitro [42].
Apart from in vitro tests, the use of primary pre-differentiated osteoblastic cells is recommended
for clinical applications regarding bone repair and regeneration since they can immediately produce
a bone matrix, which would accelerate the healing process. These cells are usually obtained from
bone chips using enzymatic extraction and then are cultured in vitro for scaling up [43,44]. However,
the restricted proliferation in vitro is considered the main obstacle regarding in vivo use of this type of
cells [45]. Therefore, there are very few studies about the direct use of pre-differentiated osteoblastic
cells for in vivo applications as compared to stem cells [46]. For instance, Gentleman et al. reported
the different quality of bone produced by different types of cells [47] and showed that osteoblasts and
adult stem cells (i.e., MSCs) produced biomimetic tissue with many of the hallmarks of native bone,
while embryonic stem cells could not present this performance.
2.2. Osteoclasts
2.2.1. General Information
Osteoclasts are multinucleate cells that have the ability to degrade mineralized bone tissue and
are vital for calcium homeostasis, bone remodeling, and repair. Activated osteoclasts flattened and
attached to the bone surface with αVβ3 integrin. The ruffled edge of osteoclasts prepares a wide
surface area of the specified membrane through which hydrolytic materials are released for natural
biodegradation [48].
Osteoclasts originate from myeloid lineage cells, and their differentiation is provided by numerous
osteotrophic molecules such as simvastatin (Sim) or PTH, 1,25(OH)2 vitamin D3, and IL-11, which
coordinate osteoclast development via specific receptors on osteoblasts and stromal cells. Osteoclast
genesis needs cell-cell interaction and communication by osteotropic molecules through specific cell
membrane proteins. It has been well documented that the interaction between pro-osteoclasts and
osteoblasts is mediated by RANK, which is an osteoclast precursor specific marker and RANKL on the
surface of osteoblasts. This interaction leads to the differentiation of pre-osteoclasts to osteoclasts [49,50].
Degradation of the mineralized bone matrix is the main function of this cell. This includes dissolution
of crystalline hydroxyapatite and proteolytic digestion of the collagenous bone matrix. The cleavage
of hydroxyapatite occurs by the production of HCl. The organic bone matrix is solubilized by several
proteolytic enzymes such as lysosomal cysteine proteinases and matrix metalloproteinases [51,52].
2.2.2. Application in BTE
Ideally, the materials implanted in the body should be completely degraded within a defined
period. This degradation depends on both chemical dissolution (physicochemical degradation) and
resorption (cellular degradation by osteoclasts) [53]. Therefore, the main use of osteoclasts is the
functional evaluation of the biomaterials designed for bone regeneration applications. On this matter,
Tortelli et al. investigated the interaction between bone cells (osteoblasts and osteoclasts) and a 3D
resorbable porous ceramic scaffold based on silicon-stabilized tri-calcium phosphate (Skelite®) to
compare it to traditional 2D cultures [54]. In another study, Karpov et al. evaluated sol-gel BGs
regarding their ability to support both osteoblast and osteoclast formation from human bone marrow
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cells [55]. The authors identified the response of osteoclasts for this biomaterial by morphology and
positive staining for tartrate-resistant acid phosphatase (TRAP) (Figure 3). Midha et al. reported that
bioactive sol-gel glass foams can be remodeled by using osteoclasts, as shown by the presence of
resorption pits on the scaffold struts in vitro [56]. Regarding the importance of using osteoclasts in
BTE strategies, Han and Zhang clarified that the absence of osteoclasts in the experiments leads to
abnormalities of in vitro bone formation, such as disorganized matrix and defective mineralization as
well as reduced osteoblast population and activity [57].
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Figure 3. The pathways and cytokines involved in the differentiation of osteoclast progenitors into
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3. Undifferentiated Cells (Stem Cells)
The use of stem cells in bone tissue repair and regeneration applications has become increasingly
important due to their supreme properties in terms of the bone healing process. Different types of stem
cells (embryonic, fetal, and adult) have been considered as suitable cell sources for bone regeneration.
All the stem cells show well-defined characteristics including the potential of self-renewal and the
ability to differentiate into specialized cells [59]. In the following sections, we comprehensively discuss
the application of all the stem cells in BTE.
3.1. Embryonic Stem Cells (ESCs)
3.1.1. General Information
The first reports regarding the successful isolation of ESCs from the inner cell mass (ICM) of
blastocysts were related to the experiments performed by two groups coordinated by Evans and Martin
in 1981 [60,61]. In addition to the mouse, scientists have also succeeded in the isolation of ESCs from
other species including non-human primates (like the rhesus monkey) and humans [62,63]. Although
there are ethical issues about the isolation of ESCs in the case of humans [64], new approaches s ch as
in vitro fertilization (IVF) and nuclear cloning have been developed to remove these problems [65].
Under the defined conditions, these cells can differentiate into all the three germ lines (Figure 4).
Generally, culturing ESCs requires a notable commitment for time a d resources, which makes
it an overwhelming process [66]. However, it is necessary to culture these cells in the most optimal
conditions because the following applications would depend on the starting sources [67]. Previously,
the use of mouse embryonic fibroblasts (MEFs) [68] or human feeders [69] as a feeder layer was the
most common method to culture ESCs since they provide a large number of growth factors required
for the robust growth of all types of ESCs. However, there are some difficulties related to MEFs
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including their complexity, non-defined components, and xenogeneic origin with respect to the culture
of human ESCs (hESCs) [70]. Therefore, the use of the human-originated feeder layers was considered
to overcome the issues associated with the MEFs. In this regard, human fetal and adult fibroblast
feeders have been applied to long-term undifferentiated growth of hESCs [69]. Other adult human
cells have also been used to culture and expand hESCs including the fallopian tube, the foreskin,
marrow-derived stromal cells, and the uterine endometrium [71]. In total, feeder cultures are not
suitable for clinical application because of the release of undefined factors into cultures. Therefore,
feeder-free systems with a defined medium were developed for culturing ESCs.
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3.1.2. Application in BTE
Human ESCs are a suitable source for bone repair and regeneration applications since they
can differentiate to unlimited numbers of all specialized lineages of the healthy bone [73]. The
possibility of derivation of osteoblasts from hESCs has been under the influence of ascorbic acid,
β-glycerophosphate, and dexamethasone [74]. In addition, it is possible to generate osteogenic cell
lineages from ESCs without the need to prepare embryonic bodies [75]. The potential of these cells
regarding the endochondral bone regeneration in vivo has also been shown in a study conducted by
Jukes et al. in 2008 [76]. However, the risk of tumor formation (tumorigenicity) in the recipients is the
main drawback regarding the use of hESCs for the clinical setting. Thus, the differentiation of them
into progenitors is suggested as an alternative to overcome the problem mentioned above. In this
regard, De Peppo et al. produced hESCs-derived mesodermal progenitors (hES-MPs) and compared
their osteogenic potential to BM-MSCs [77]. They found that transcriptional modifications occurring
during hES-MP derivation lead to a gene expression profile, which is highly similar to that of hMSCs.
The authors concluded that the hES-MPs with the immune privileged characteristics (low expression
of HLA class II) and increased proliferation properties could serve as a valuable cell source for tissue
engineering application. In another study, Taiani et al. produced murine ESCs-derived osteoblasts for
using in impaired fracture healing in the mouse [78]. For this aim, they loaded the prepared cells in a
Appl. Sci. 2019, 9, 174 8 of 49
3D collagen I gel and implanted the cells into the ovariectomized fractures. The authors observed the
stem cell-derived osteoblasts at the fracture site after four weeks of the implantation through in situ
hybridization histochemistry. The in vivo micro-computed tomography (µCT) imaging and histology
analyses confirmed that ES cell-derived osteoblasts loaded on collagen I matrix can improve bone
formation and restore fracture healing in vivo.
3.2. Induced Pluripotent Stem Cells (iPSCs)
3.2.1. General Information
The iPSCs are a new type of pluripotent stem cells that are generated by reprogramming
technology. Yamanaka et al. introduced this approach by developing the iPSCs using the insertion of
four specific genes encoding transcription factors (Oct4, Sox2, cMyc, and Klf4) into the adult cells. The
lack of ethical issues is considered as the most important advantage of these cells over the embryonic
cells. Moreover, the risk of immune rejection is solved since autologous cells could be used to generate
transplants. However, there are some concerns about their possibility of tumor tissue formation
in vivo.
The iPSCs technology is considered as a new promise for scientists who work on novel therapies
for damaged or diseased tissues. The iPSCs can be successfully expanded through the same culture
protocols developed for the ESCs, which may maintain their morphology, molecular signature,
and differentiation potential [79–81]. Under the appropriate condition, the iPSCs reprogrammed
are able to differentiate into other cell types. For example, different functional stem cells such as
hepatocytes [82], neural cells [83], and osteogenic cells [84] have been derived from iPSCs. In this
regard, greater attention was paid toward the use of these cells in bone tissue repair and regeneration.
As an illustration, Phillips et al. in 2014 reported a successful differentiation of iPSCs toward the bone
tissue both in vitro and in vivo [85].
3.2.2. Applications in BTE
Compared to other cell types, the use of iPSCs for BTE applications opens a new horizon. In order
to differentiate iPSCs toward osteogenic lineages, the use of protocols applied for ESCs was suggested
since both cell types show similar properties [86]. One of the ways proposed for preparing iPSCs
with a commitment towards osteogenic lineage is genetic manipulations. On this matter, Tashiro et al.
transduced an exogenous Runx2 gene into mouse iPSCs via adenoviral vectors [87]. This gene
transduction resulted in a higher production of ALP and calcium levels in the transduced cells as
compared to controls. This study is considered as one of the first experiments regarding the production
of iPSC-derived osteoblasts. As a novel approach, the use of some specific anti-miRNA was reported
as an effective way of improving osteogenic differentiation. For instance, Okamoto et al. showed that
the transfection of anti-miRNAs of 124a, 181a, 10a, 10b, 9-3p, and 19b into mouse iPSCs significantly
promote the osteoblastic differentiation [88].
Culturing iPSCs in the osteogenic medium is another proposed approach for obtaining osteogenic
lineages. In this regard, Kao et al. cultured iPS cells in an osteogenic medium containing
low-glucose DMEM supplemented with 15% FBS, 50 µg/mL ascorbate-2-phosphate, 10 nmol/L
dexamethasone, and 10 mmol/L β-glycerophosphate for two weeks [89]. They used resveratrol to
promote differentiation of iPSCs into osteocyte-like cells, protect the iPSC-derived osteocyte-like cells
from glucocorticoid-induced oxidative damage, and reduce the risk of tumorigenicity of iPSCs.
Even though the production of iPSC-derived osteoblast-like cells is now a common process, the
in vitro and in vivo stability of the generated cell’s phenotype is even more significant. This is a
very important issue when iPSCs are used in in-vivo experiments. In this regard, Bilousova et al.
reported the expression of osteoblast markers (e.g., RUNX2) in the implanted mouse iPSC-derived
osteoblasts together with Gelfoam sponges at 12 weeks of post-implantation [90]. Their results proved
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the effectiveness of appropriate scaffolds in improving the osteogenic differentiation of iPSCs and
bone formation in vivo.
It has been documented that BM-MSCs have a limited differentiation potential due to their
senescence in vitro. To address this problem, the use of iPSCs-derived MSCs (iMSCs) was suggested
since this source provides an unlimited source of MSCs. For example, Sheyn et al. differentiated
human iPSCs toward functional MSCs for use in bone repair and regeneration [91]. In order to
direct differentiation of iPSCs towards MSCs, the authors exposed embryoid bodies to TGF-β for a
short period. They could prepare two types of iMSCs including early and late iMSCs. The in vitro
results revealed that, even though both cell types maintained their multi-differentiation potential,
the early iMSCs showed higher osteogenic activity as compared to other cells (the late iMSCs and
BM-MSCs). Moreover, the in vivo results indicated that the ectopic administration of the early iMSCs
overexpressing BMP6 resulted in a substantial bone formation in comparison to the other groups. The
authors concluded that iMSCs could exhibit a self-renewal property without tumorigenic activity and
considered them as very good candidates for bone regeneration.
3.3. Fetal Stem Cells
In pregnancy, two fetal membranes, i.e., the amnion and the chorion, surround the human fetus
(Figure 5). The amnion is a thin layer that closely covers the human embryo. This membrane is filled
with the amniotic fluid (AF), which serves as a protective environment for the developing embryo
or fetus. The chorion is the outermost fetal membrane, which exists during pregnancy between
the developing fetus and mother. The fetal tissue possesses stem cells in its structures, which are
remarkably different from embryonic and adult stem cells [92,93]. These cells have been defined as
a distinct type of stem cells with their own properties [94]. Human fetal stem cells are described as
cells from the end of the two months of conception until birth, which is isolated from the fetal tissues
and have the capacity to preserve clonality, high proliferative ability, and plasticity [92]. Prior studies
have noted the superiority of fetal stem cells compared to embryonic and adult stem cells in terms of
safety due to the low risk of teratomas forming and transmitting infection [95]. The growing body of
evidence suggests significant heterogeneity within a population of fetal stem cells, which depends on
the tissue of origin [96,97]. Fetal stem cells have been identified in umbilical cord blood (UCB-MSCs,
UCB-HSCs, EPC) [98,99], Wharton’s jelly (UCMSCs), amniotic fluid (AF-HSCs, AF-MSCs, and AFSCs),
amniotic membrane (AECs, AMSC, and ADSCs), placenta (CMSCs and CTCs), and even maternal
circulation (PAPCs) [100–104]. Fetal-derived stem cells have been shown to exhibit high proliferative
ability to resemble embryonic stem cells [105].
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3.3.1. Amniotic Fluid-Derived Stem Cells (AFSCs)
3.3.1.1. General Information
The human amniotic fluid (hAF) is a clear, yellow fluid, which has important roles for the growing
fetus including facilitating the exchange of nutrients, water, and biochemical products between the
mother and the fetus as well as protection of the fetus. As previously well documented, this liquid is
composed of embryonic and fetal cells derived from all the three germ layers (ectoderm, mesoderm,
and endoderm). Hence, hAF is currently used as a suitable source of human stem cells that may be
used in different biomedical fields. Actually, the first report on the presence of progenitor cells as small,
nucleated round cells (hematopoietic progenitor cells) in the hAF was published in 1993 [107]. It was
later reported that there is also multilineage non-hematopoietic cells in the hAF [108]. This liquid
as a novel source of MSCs with therapeutic capability was introduced to the biomedical sciences in
2003 [109]. These cells were initially named human amniotic fluid stem cells (hAFSCs) [98]. To isolate
and culture these cells, about 2 mL of amniotic fluid is sufficient. In a cell culture condition, they are able
to double up to 250 times without any detectable loss of chromosomal telomere length [98]. Like other
MSCs, they have the potential for self-renewal and multi-lineage differentiation. The differentiation
of hAFSCs into the cells from the three embryonic layers including hepatocytes (endoderm) [98],
osteoblasts (mesoderm) [98], and neurocytes (ectoderm) [110] has been previously confirmed. The
presence of AFSCs in the other mammals such as mice [110], rats [111], rabbits [112], sheep [113],
and pigs [114] was also reported.
3.3.1.2. Applications in BTE
One of the first reports on the osteogenic potential of AFSCs is related to the original work of
De Coppi et al. in 2007 [98]. The authors observed the differentiation of these cells into functional
osteoblasts (mesoderm) after culturing in an osteogenic medium in vitro, which produced mineralized
calcium as well as the expression and secretion of ALP (a surface marker of osteoblasts). In order to
provide a proof of concept, the authors subcutaneously implanted this type of cell with or without
3D printed alginate/collagen scaffolds into outbred athymic nude (nu/nu) mice. The in vivo results
revealed a highly mineralized tissue in the animals that received the cell-seeded constructs, while no
sign of mineralization was observed in the animals grafted by unseeded scaffolds. Rodrigues et al.,
in a comparative study, evaluated the behavior of hAFSCs and BMSCs in different culture systems (2D
and 3D) to determine which cell type is more suitable for BTE applications [115]. Their results showed
that both cells differentiate into the osteogenic cell lineage in the 2D culturing environment, which was
confirmed by the production of a mineralized ECM. However, enhanced mineralization of the ECM
was observed in AFSCs when compared to BMSCs. In contrast, the less mineralized ECM was observed
in the AFSC scaffolds in comparison to BMSCs constructs, when cultured in the 3D system (starch
and poly (e-caprolactone) (SPCL) scaffolds). The assessment of expression patterns of bone-related
markers (e.g., ALP activity and RUNX-2 expression) and different timing of differentiation revealed
that cell origin and the culture environment have remarkable effects on the differentiation process into
the osteogenic lineage. With respect to some priorities such as higher proliferation, the authors stated
that AFSCs could be a good alternative to BMSCs for BTE applications.
3.3.2. Amniotic Membrane Stem Cells (AMSCs)
3.3.2.1. General Information
Human amniotic membrane (hAM) or amnion as the innermost layer of the fetal membranes is an
avascular stromal matrix. This membrane has been widely used in tissue engineering based-approaches
for healing different tissues including eyes [116], skin [117], teeth [118], and the cardiovascular
system [119]. Additionally, the hAM is clinically used as a tissue with therapeutic possibilities for
repairing different burns [120], leg ulcers [121], oral and maxillofacial disorders [122], and stroke [123].
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Histologically, the amniotic membrane is composed of five distinct layers including an epithelial cell
monolayer, an acellular basement membrane layer, a compact layer, a mesenchymal cell layer, and a
spongy layer [124]. HAM as a stem cell source benefits from several advantages such as a good yield of
cells as well as not needing invasive or expensive procedures [125]. Moreover, the use of AM-derived
stem cells for TE applications does not face ethical issues. Human amniotic epithelial cells (HAECs)
and human amniotic mesenchymal stromal cells (HAMSCs) are the main stem cell types isolated and
characterized from the hAM. It has been well documented that both of the cells possess stemness
characteristics including the ability to self-renew [126], immunomodulation [127], and differentiation
into cell lineages of different germ layers [128]. The isolation procedure of these cells is fairly easy and
is performed via previously proposed methods [106,129–131].
Recently, the use of HAMSCs together with a scaffold for tissue engineering strategies has grown
with interest [132]. HAMSCs were first introduced by In’t Anker et al. as cells with the potential of
osteogenic and adipogenic differentiation [93]. According to the International Society for Cellular
Therapy, these cells are formally named amniotic membrane-human mesenchymal stromal cells
(AM-hMSCs) [133]. In a cell culture condition, AM-hMSCs display a spindle-like shape morphology
and are able to attach to tissue culture plastic [134]. In addition to human, the presence of these cells
has been reported in other mammals such as cat [135], horse [136], and bovine [137].
3.3.2.2. Applications in BTE
In order to evaluate the osteogenic differentiation potential of HAM-derived cells, Dıaz-Prado et
al. examined the presence of the bone-related markers in the cultured cells [138]. Their results revealed
that both cell populations have similar surface expression profiles of mesenchymal progenitors (CD90,
CD44, CD73, CD166, CD105, and CD29). However, the differentiation potential of hAMSCs was
much greater than hAECs based on the results of Alizarin Red staining and qRT-PCR (osteopontin
(OP) and ALP). Other studies also confirmed the osteogenic potential of these cells. For example,
Jiawen et al. showed the in vitro and in vivo potential of hAECs regarding bone regeneration [139].
They assessed an in vitro osteogenic differentiation process of the cells via biochemical staining,
qRT-PCR, and immunofluorescence staining. The in vivo osteogenesis activity of hAECs was evaluated
by implantation of the cells alone or in combination with β-tricalcium phosphate (β-TCP) scaffolds.
The in vitro results showed up-regulation of bone-related genes (RUNX2, osterix (Osx), ALP, collagen
I, and OP) with positive biochemical staining for osteoblasts. Moreover, the up-regulation of TGF-β
was observed, which is related to the epithelial-mesenchymal transformation process involved in
the osteogenic differentiation of hAECs. The in vivo implantation of the hAECs-seeded scaffolds
led to enhanced bone reconstruction as well as reduced the early host immune response to the
implanted scaffolds.
To show the osteogenic potential hAMSCs, Rodríguez-Fuentes et al. in 2013 tried to differentiate
hAMSCs into osteoblastic-like cells by using co-incubation with bovine bone matrix Nukbone®
(NKB) [140]. The authors prepared the NKB disks and placed them in cell culture plates in three
different conditions including (1) positive control (AM-hMSC seeded on polystyrene disk with
H-DMEM supplemented with ascorbic acid, dexamethasone, and β-glycerophosphate), (2) negative
control (AM-hMSC cultured on polystyrene disk in H-DMEM), and (3) AM-hMSC with H-DMEM
seeded on the NKB disk as experimental group. The obtained results showed more visible signs
(over-expression of bone-related genes) of osteogenic differentiation of the cells cultured on the NKB
disk when compared to other groups.
In a comparative study, Si et al. investigated the osteogenic potential of three different types of
stem cells including hAFMSCs, hAECs, and hBMSCs both in vitro and in vivo [141]. The obtained
results revealed that there were significant differences among the cells in terms of cell morphology and
proliferation and the immuno-phenotypical profile. The authors found that, although hAECs exhibited
a confirmed osteoblastic differentiation capacity, hAFMSCs and hBMSCs showed a higher osteoblastic
phenotype. All the cells were seeded onto β-TCP scaffolds and were subcutaneously implanted into
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the nude mice to further investigate the osteogenic capacity. The immuno-histochemical analysis
of the samples confirmed the up-regulation of the osteogenic markers (OP and BGLAP) in all three
groups (the β-TCP scaffolds seeded with hAECs, hAFMSCs, and hBMSCs) as compared to the controls,
which indicates the in vivo osteogenic potential of all three cell sources. However, there was a different
expression profile of genes involved in ossification among the cell types since hAFMSCs and hBMSCs
show a higher osteoblastic phenotype as compared to hAECs.
3.3.3. Chorion Mesenchymal Stem Cells (Ch-MSCs)
3.3.3.1. General Information
In humans and other mammals, the chorion is the outermost fetal membrane around the embryo,
which exists during pregnancy between the fetus and mother. This tissue is comprised of two layers
including an outer sheet (formed by the trophoblast) and an inner sheet (formed by the somatic
mesoderm). The somatic mesoderm contains fibroblast-like cells called chorion stromal cells (CSCs).
These cells show characteristics of MSCs under appropriate cell culture conditions [142,143]. They
have very close features with human AMCs due to their strong similarity of origin. The differentiation
potential of Ch-MSCs into osteogenic, chondrogenic, and adipogenic lineages is significantly higher
than MSCs derived from other sources including AM-MSCs [144]. Similar to other fetal-originated
stem cells, the isolation of Ch-MSCs faces minimal ethical and legal barriers. The isolation protocol
of these cells from early-term, mid-term, and end-term gestational fetal membrane includes a simple
procedure in which maternal decidua was mechanically removed and followed by enzymatic digestion
of trophoblast layers and reticular stromal layers with collagenase [93,106,129,131].
3.3.3.2. Applications in BTE
The biological characteristics of Ch-MSCs have been evaluated by Gonzalez et al. to show the
differentiation, immunosuppressive, and angiogenic capacity of these cells [145]. Their results revealed
that these cells could express the osteogenic markers after specific inductions. In addition, these cells
showed an excellent immune privilege and superior angiogenic activity, which makes them ideal
candidates for TE strategies. These data have also been confirmed in a recently published study, which
shows the ability of Ch-MSCs to differentiate toward osteogenic lineages [146]. Moreover, Kusuma
et al. evaluated the ectopic bone formation by Ch-MSCs in comparison with decidua-derived MSCs
(DMSCs) [147]. The in vitro experiments showed that both types of stem cells are capable of osteogenic
differentiation. The in vivo results showed that the subcutaneous implantation of bromo-deoxyuridine
(BrdU)-labeled CMSCs and DMSCs together with hydroxyapatite/tricalcium phosphate particles
could form the ectopic bone at eight-weeks post-transplantation in SCID mice. The authors concluded
that these cells could be considered proper alternatives for BTE strategies.
3.4. Adult Stem Cells
These stem cells are tissue-resident units, which provide homeostasis and regeneration after any
damage to the human body. In the damaged tissues, adult stem cells are found in the non-proliferating
state in which their cell cycle is reversibly arrested (known as quiescence). In this state, their stemness is
preserved by preventing precocious differentiation, which results in keeping a pool of undifferentiated
cells. These tissue-specific cells have been identified in the adult tissues of bone marrow, skin, muscle,
nervous system, etc. [148]. Similar to all post-natal cells, mesenchymal stem cells present in the
umbilical cords of newborn babies are recognized as adult stem cells. In the following sections,
we present the well-documented sources of adult stem cells used for bone reconstruction strategies
and discuss their potential for bone tissue repair and regeneration.
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3.4.1. Bone Marrow Stem Cells (BM-MSCs)
3.4.1.1. General Information
Bone marrow (BM) is a flexible spongy tissue inside the large bones where new blood cells are
produced. Two types of BM including red marrow and yellow marrow have been identified. Red
bone marrow is responsible for the production of red blood cells, platelets, and most white blood cells,
while the rest of white blood cells develop in yellow marrow [149].
Two major types of stem cells can be found in BM including hemopoietic (which can produce
blood cells) and stromal cells (which can produce fat, cartilage, and bone). Bone marrow stromal
stem cells (BMSSCs) are postnatal stem cells, which are also known as BM-MSCs. BM-MSCs were
initially identified and characterized from bone marrow by Friedenstein et al. in the 1980s through
an in vitro culture and transplantation in laboratory animals [150–152]. These cells comprise only
0.01% of the total nucleated cells in the bone marrow. Therefore, they are usually concentrated to
use in the next steps of experiments. Human BM-MSCs are routinely harvested by a simple method,
i.e., aspiration from the iliac crest in humans [153]. However, the isolation procedure of these cells is
different in other animals. For example, the aspiration of tibia and femur has been standardized to
isolate BM-MSCs from mouse and rabbit laboratory animals [154,155]. BM-MSCs as the most universal
source of MSCs are identified through some criteria including the formation of clonogenic adherent cell
clusters, fibroblastic morphology, and the potential to differentiate into all the three lineages including
ectoderm [156,157], mesoderm [158,159], and endoderm [160,161]. To characterize BM-MSCs, a number
of positive and negative surface antigens have been recommended by the International Society for
Cellular Therapy [162]. These surface markers are used to purify BM-MSCs by fluorescence-activated
cell sorting (FACS) as well as the magnetic-activated cell sorting (MACS). In addition, the use of
Percoll gradient centrifugation and adherence to tissue-culture treated plastics are proposed as more
simple techniques to purify BM-MSCs [163]. BM-MSCs can be used as undifferentiated or fully
differentiated cells for TE applications. Undifferentiated forms of BM-MSCs are obtained through the
culture in defined serum-free media or pre-screened fetal bovine serum. Fully differentiated cells can
be obtained through physical, chemical, and mechanical approaches exerted on BM-MSCs [164–166].
These cells are used for orthopedic applications in vitro and in vivo. The reasons are summarized as
the rapid proliferation, induction of osteogenesis, angiogenesis, and easy differentiation into osteogenic
lineages [167,168]. As a result, more research has been conducted to treat various bone disorders using
BM-MSCs or BM-MSCs-seeded constructs [169].
3.4.1.2. Applications in BTE
Similar to other stem cells, this type of cells can undergo osteogenic differentiation in vitro when
cultured in the presence of dexamethasone, inorganic phosphate, and ascorbic acid [170,171]. The
differentiation of BM-MSCs toward osteoblastic lineage cells is regulated through various systemic
hormones (e.g., estrogens) and local growth factors. The bone morphogenetic protein (BMP) family,
the transforming growth factor-beta (TGF-β), and the fibroblast growth factor-2 (FGF-2) are the most
well-defined factors regarding the osteogenic differentiation [172].
The therapeutic effects of BM-MSCs are associated with the secretion of large amounts of different
bioactive molecules (e.g., FGF-2, Ang-1, and G-CSF), which provide a regenerative microenvironment
with a trophic activity for the damaged bone tissue [173]. In addition, BM-MSCs homing to the sites of
bone tissue injury is considered another factor that enhances their therapeutic effect [174].
It has been reported that only a subset of high-proliferating single colony-derived BM-MSC
clones (60%) is able to form ectopic bone tissue after in vivo transplantation into immunocompromised
mice [175,176]. However, there are a large number of successful bone healing procedures using these
cells (direct injection or in combination with 3-D scaffolds) in both calvarial and long bones in different
animal models [177–179].
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Due to their supreme properties, BM-MSCs have been used in preclinical and clinical models for
repair and regeneration of the bone [180,181]. With the aim of enhancing the total-body bone mineral
content and subsequent osteogenesis in children with imperfect osteogenesis, Horwitz and colleagues
conducted the first clinical trials with BM-MSCs [182]. Since then, a large number of studies have been
performed on these cells for treating patients who suffer from osteoarthritis and bone defects [183].
3.4.2. Adipose Tissue-Derived Mesenchymal Stem Cells (ASCs)
3.4.2.1. General Information
The origin of adipose tissue (AT) is the mesodermal layer of the embryo and develops during
pre-natal and post-natal growth. Histologically, two types of adipose tissue were identified including
white adipose tissue (WAT) and brown adipose tissue (BAT). There are some morphological and
functional differences between the two AT types. Compared to BAT, WAT is more abundant in the
human body [184]. One of the first reports on the cell isolation from AT belongs to Rodbell et al. in
the early 1960s [185]. Cellular components in AT contain adipocytes and a heterogeneous set of cell
populations, i.e., the stromal vascular fraction (SVF) (Figure 6). The SVF acts as a supporting cell
population for adipocytes and comprises adipose-derived stem cells (ASCs), vascular endothelial cells,
vascular smooth muscle cells (VSMCs), and leukocytes. ASCs as the most important cells of AT have
been isolated from both white and brown tissues with different characteristics. These cells were first
formally recognized in human lipoaspirate by Zuk et al. in 2001 [186]. Among different methods,
the liposuction technique is widely used to harvest ASCs from the human body due to its relative ease
of execution. Furthermore, as a good point, the function of ASCs is not affected by the lipo-aspiration
procedure. Apart from ASCs, a variety of terms have been applied to describe these cells including
adipose-derived adult stem cells (ADAS), adipose-derived stromal cells (ADSCs), adipose-derived
mesenchymal stem cells (Ad-MSCs), lipoblasts, pericytes, pre-adipocytes, and processed lipoaspirate
(PLA) cells [187].
According to the International Fat Applied Technology Society (IFATS), the term of ASCs is
the standard name for the isolated, plastic-adherent, multipotent cell population. The isolation
procedure of ASCs is a simple process in which lipoaspirate adipose tissue is digested by collagenase
(type IV), which is followed by centrifugation to separate the stromal population from the
adipocytes [188]. Similar to BM-MSCs, ASCs can be purified by using well-established approaches
such as FACS and MACS techniques. In the culture situation, these cells show the primary
characteristics of MSCs including attachment to plastics, fibroblast-like morphology, and differentiation
to different cell lineages including osteoblasts [189], chondrocytes [190], endothelial cells (ECs) [191],
cardiomyocytes [192], and neural cells [193]. Similar to other MSCS, ASCs express some cell surface
markers, which can be used for their characterization. Like other MSCs, ASCs serve as a “secretome”
and secret regulatory proteins and growth factors in the extracellular environment [194]. Therefore,
these cells contribute to angiogenesis and suppression of inflammation and, thereby, induce cell
migration and proliferation in the body [195,196]. Moreover, the ease of availability, a high proliferation
rate, and less discomfort and morbidities with the ASCs isolation are considered as the ratiocinations
for increasing use of these cells for TE applications [187]. From an immunological point of view,
ASCs are classified as immunosuppressive cells due to the lack of MHC class II antigens on their
surface [197].
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3.4.2.2. Applications in BTE
The ease of availability, high yield of cell isolation, and excellent proliferation rate are considered
the main reasons for the use of ASCs in bone regeneration [199]. It has been shown that one gram
of adipose tissue yields about 5 × 103 stem cells, which is 500-fold greater than the numbe of cells
obta n d from one gram of bone marrow [200–202]. H wev r, some studies report a lower osteogenic
capacity of ASCs in compar son to BMSCs. A an illu tration, Im et al. compared the osteogenic
activity of ASCs versus BM-MSCs in vitro [203]. They cultured both ste cell types in osteogenic
medium containing dexamethasone, β-glycerophosphate, and ac d ascorbic. The results reve l that
82% and 92% of the BM-MSCs a e positive cell for ALP staining after two an three w eks of culturing
in the osteog nic edium, respectively. In the case of ASCs, these percentages we e 28% and 45%,
which confirms the higher osteog nic capacity of the BM-MSCs in comparison to ASCs.
In vitro osteoge ic differentiation of ASCs may b achieved aft r 14 days of cultu ing in a
conditioned medium supplemented with 1 nM dexam thasone, 2 mM b-glycerolphosphate, and 50 lM
ascorbate-2-phosphate [188,204]. However, other approaches have also been documented as reliable
methods for diff rentiating ASCs as osteoblastic-like cells (Figure 7). For example, Chou et al. clarified
that the combination of reco binant huma BMP-2 and ASCs can result in an improvement in the
osteogenic potential in vivo [205].
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The in vivo differentiation of juvenile and adult ASCs into osteogenic lineages was first reported
by Cowan et al. [207]. They implanted the ASCs-seeded apatite-coated PLGA scaffolds in the
critical-size defects of mice. The results of the implantation of samples after two, four, eight,
and 12 weeks showed that the juvenile ASCs-seeded apatite-coated scaffolds could form new bone
(25%, 80%, 70%, and 85% bone formation, respectively) at the damaged site, while less bone formation
(30 , 55 , 50%, and 70% bone formation, respectively) was observed in the groups treated with the
adult ASCs/scaffolds. Moreover, they evaluated the effect of apatite coating on the progression of
the new bone formation. The role of the apatite coating in promoting the osteogenic capacity of the
osteoblast-seeded constructs further confirms the influence of scaffold biomaterial on cell activity and
fate. At the same time (2004), the first report on the clinical use of hASC–fibrin glue for treating an
extensive craniofacial injury in a seven-year-old girl was published by Lendeckel et al. [208].
Evaluating the potential tumorigenic feature of ASCs before taking any clinical experiments is a
necessary step. According to the literature, there is significant controversy about the effect of ASCs on
tumor growth since some studies state ASCs may favor the growth of tumor cells, while other studies
contradict these results [209].
3.4.3. Umbilical Cord Mesenchymal Stem Cells (UC-MSCs)
3.4.3.1. Umbilical Cord Wharton’s Jelly-Derived Mesenchymal Stem Cells (WJMSCs)
General Information
In mam als, the umbilical cord is comprised of umbilical arteries and veins surrounded by
Wharton’s jelly (WJ). The term WJ was initially proposed by an English physician and anatomist in
1656 [210]. In humans, the main components of the WJ consist of glycosaminoglycans (hyaluronic acid
and chondroitin sulfate) and collagen fibers. The cellular components of this gelatinous tissue include
different cell types such as fibroblasts, myofibroblasts, smooth muscle cells, and a subset of stromal
cells [211]. The presence of MSCs in the WJ was not determined until 2004 when fibroblast-like cells of
this tissue were proven to be MSCs [212]. The WJ-MSCs can be isolated from the umbilical cord matrix,
which consists of two distinct regions known as inter-vascular and sub-amnion regions. The number
and nature of these cells are different from other regions of UC including peri-vascular and vascular
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endothelium zones [213]. Similar to the procedure of human WJ collection, the isolation of WJ-MSCs is
noncontroversial and without ethical issues [214].
These cells have also been isolated from other mammals including bovine [215], horse [216],
and cat [217]. Like other MSCs, WJ-MSCs possess plasticity characteristics and, thereby, may
differentiate into cells with origins of ectoderm (e.g., neurons) [218], mesoderm (e.g., osteoblasts) [219],
and endoderm (e.g., hepatocytes) [220]. However, a number of advantages have been proposed
for these cells in comparison with other MSCs including faster proliferation rate, greater
expansion capability, immunosuppressive properties, and better efficiency in terms of therapeutic
characteristics [212]. Two of the main methods for isolation of the WJ-MSCs include the density
gradient centrifugation approach and enzymatic digestion [221]. It has been shown that the enzymatic
degradation approach is the most efficient for harvesting the WJ-MSCs. Due to the large size of the
UC, the number of isolated cells is usually high (approximately ~1.5 × 106 cells/cm of the umbilical
cord) [222]. The WJ-MSCs with appropriate features such as immunosuppressive characteristics
may be ideal candidates for TE and cell-based therapy strategies [223]. In addition, these cells
may support the expansion of other stem cells to excrete various cell growth factors, chemokines,
and cytokines [224,225].
Applications in BTE
WJ-MSCs are being currently considered as an alternative to BM-MSCs for bone repair and
regeneration strategies. It has been previously reported that this cell type is able to give rise to
osteogenic lineages after culturing in the osteogenic medium [226]. In addition to the ability to
osteogenic differentiation, WJ-MSCs are ideal candidates for BTE with respect to their abundant
resources, no damage procurement, and low immunogenicity. Moreover, Chen et al. showed
WJ-MSCs do not undergo a malignant transformation during long-term culturing (up to 15 passages)
in serum-free medium [227]. However, it has been shown that the osteogenic potential of WJ-MSCs
is lower than BM-MSCs in vitro and in vivo conditions [228,229]. In order to address this issue, the
genetic engineering of these cells has been proposed as an appropriate approach. On this matter,
Wang et al. inserted the gene encoding Ost into WJ-MSCs to improve their osteogenic capacity [230].
They showed that transfection of Osx into the cells results in enhanced ALP activity without any
adverse effects on the cell proliferation rate. The implantation of Osx-overexpressing WJ-MSCs into
the subcutaneous pocket of nude mice resulted in a higher ectopic bone formation in comparison to
the non-transfected WJ-MSCs after four weeks.
The use of WJ-MSCs together with 3D scaffolds has been applied for accelerating bone repair and
regeneration. As illustrated, Diao et al. evaluated in vivo osteogenesis of human WJ-MSCs-seeded
nano-hydroxyapatite/collagen/PLA composite (nHAC/PLA) scaffolds [231]. In order to reveal the
osteogenic potential, the authors implanted the constructs in the subcutaneous region of Balb/c nude
mice for four to 12 weeks. The obtained results revealed that the cell-seeded scaffolds could improve
ectopic bone formation with human origin in vivo. In another study, Chen et al. implanted human
WJ-MSCs-seeded macroporous calcium phosphate cement (hUCMSC-CPC) in critical-sized cranial
defects in athymic rats for revealing their osteogenic potential in comparison with hBM-MSCs-seeded
CPC (hUCMSC-CPC) [232]. The in vitro results showed that both cell types possess high osteogenic
expressions of ALP, BGLAP, collagen I, and RUNX2. In addition, the in vivo data indicated higher
bone mineral density (9% and 19% for hUCMSC-CPC and hBMSC-CPC, respectively), larger new bone
area fraction (57% and 88% hUCMSC-CPC and hBMSC-CPC, respectively), and higher new blood
vessel density (15% and 20% hUCMSC-CPC and hBMSC-CPC, respectively) compared to the controls
(CPC alone) at 24 weeks’ post-implantation. Although hBMSC were better in terms of all the examined
parameters, the authors concluded that WJ-MSCs are an ideal cell source for BTE applications, which
can be used instead of hBMSCs.
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3.4.3.2. Umbilical Cord Blood-Derived Mesenchymal Stem Cells (UCB-MSCs)
General Information
Umbilical cord blood (UCB) is currently recognized as a rich source of hemopoietic
stem/progenitor cells. The first umbilical cord blood transplantation was performed in 1988, and the
results demonstrated its therapeutic potential as a reliable cell-based therapy. Although the HSCs
have been initially more widely used for various clinical situations, recently, the UCB-derived MSCs
have also attracted attention for use in biomedical fields. Today, umbilical cord blood (UCB) as a
part of UC is recognized as an interesting source of MSCs [233]. Like other parts of UC, the cell
isolation of UCB takes advantage of the painless and non-invasive procedure without any damage
to the mother or infant [234]. Up to now, a variety of methods have been proposed to collect UCB
as the source of human UCB-MSCs [235]. The isolation procedure of MSCs of UCB is laborious
and time-consuming, which usually results in a low rate of success. The most effective method for
collecting UCB is the cannulation of the umbilical vein, which is followed by blood collection into
a sterile bag containing citrate phosphate dextrose or acid citrate dextrose anti-coagulant (ACD-A)
buffer [236,237]. The isolation of UCB-MSCs is performed by using Ficoll density centrifugation media
at the appropriate relative centrifugal force (RCF). After centrifugation, the formed interface layer is
collected and washed with PBS. Lastly, the resulting solution is centrifuged and washed (with PBS)
several times and is transferred into cell culture dishes. The cells were cultured using suitable culture
media for several days. By washing cells, non-adherent cells were removed, and only the adherent
cells with a fibroblastic spindle-like shape (i.e., MSCs) may remain [238]. It has been previously proven
that there is no significant difference between the collections obtained from Caesarean and vaginal
delivery in terms of the net yield of nucleated cells [239]. A few practical tips have been suggested to
increase the yield of isolated cells including blood collecting from long gestations and high infant and
placenta weights as well as applying short intervals between deliveries of the baby and clamping of
the cord [240].
Similar to UC-derived MSCs, the UCB-MSCs are immunosuppressive modulators that can be used
for allo-transplantations and xeno-transplantations [241,242]. However, the differentiated UCB-MSCs
have also been used as a cell source in several studies. Under appropriate induction conditions
(culturing in osteogenic medium), UCB-MSCs can differentiate into cell lineages of endoderm [243],
mesoderm [244], and ectoderm [245]. This ability has also been observed in the UCB-MSCs obtained
from other species such as horses [246]. The use of these cells with or without scaffolds for regeneration
of skeletal system disorders has been applied in various studies [247,248].
Applications in BTE
Previous reports have confirmed that UCB-MSCs are able to undergo osteogenic differentiation
after culturing in the osteogenic medium [245,249,250]. The advantages of this type of cells for BTE
applications are counted for their availability, less invasive method, and osteogenic capacity. In 2006,
Kern et al. compared UCB-MSCs with BM-MSCs and ASCs in terms of their morphology, the success
rate of MSCs isolation, colony frequency, expansion potential, multiple differentiation capacities,
and an immune phenotype [251]. Their results revealed that there are no significant differences among
the cells regarding the morphology and immune phenotype. However, the isolation rate of MSCs was
different for the cell sources, i.e., 100% for BM and AT, but only 63% for UCB. In addition, the colony
frequency was highest in AT and lowest in UCB. On the other hand, the highest proliferation capacity
belonged to UCB-MSCs, while the lowest one was for BM-MSCs. With respect to osteogenic potential,
the authors concluded that UCB is an attractive alternative to BM in isolating MSCs.
The in vivo osteogenesis potential of UCB-MSCs has also been documented in some previously
published studies. For example, Liu et al. examined the osteogenesis of human UCB-MSCs on
the partially demineralized bone matrix (pDBM) in critically-sized defects of athymic rats [247].
The analyses of the implanted samples confirmed the formation of new bone in the animals treated
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with osteogenically induced UCB-MSC/pDBM composites at six and 12 weeks’ post-implantation. The
authors stated that pDBM is able to support in vitro and in vivo osteogenic differentiation of human
UCB-MSCs as well as human UCB-MSCs, which can be considered an alternative cell source for BTE
applications. In another study, Jang et al. implanted canine UCB-MSCs together withβ-TCP powder for
enhancing osteogenesis in bone defects of a dog model [242]. They implanted 700 mg of β-TCP mixed
with 1 × 106 UCB-MSCs into a 1.5 cm diaphyseal defect in the radius of Beagle dogs. After 12 weeks of
implantation, the samples were analyzed using H&E, toluidine blue, and Villanueva-Goldner staining.
The obtained results of bone histomorphometry revealed a greater area of new bone formation in
the animals treated with the UCB-MSCs/β-TCP group (10.92 ± 2.74% of total damaged area) in
comparison to the control (4.08 ± 2.08% of total damaged area).
3.4.3.3. Endothelial Progenitor Cells (EPCs)
General Information
In 1997, Asahara et al. published a paper in which they described the origin of endothelial
progenitor cells from CD34+ mononuclear cells (MNCs) [252] Subsequently, Murohara and co-workers
demonstrated that umbilical cord blood is a rich source of endothelial progenitor cells. Apart from
peripheral blood, these cells can be isolated from bone marrow aspirates [253]. The isolation processes
include the use of adherence culture of total mononuclear cells (for non-adherent cells) or the use of
magnetic microbeads coated with antibodies (e.g., anti-CD133, CD34, or CD31) for mononuclear cell
sorting. After being isolated, the cells are cultured on fibronectin-coated dishes in the defined media
containing specific growth factors (e.g., VEGF, bFGF, and EGF) [254].
There is evidence regarding the effectiveness of the UCB-derived EPC transplantation for treating
acute and chronic disease [255,256]. Existing research identifies the critical role of signaling molecules
produced by EPCs, which are responsible for their therapeutic effects in human patients [257]. These
cells have a spindle-shaped morphology and express both endothelial and monocyte markers [258].
Ingram et al. claim that a subtype of EPCs such as endothelial colony-forming cells (ECFCs) have
an outgrowth ability in blood vessels [259]. ECFCs are identified by high proliferative capacity and
vessel forming ability, which is positive for endothelial markers and negative for hematopoietic cell
markers [258]. Furthermore, high numbers of ECFCs are found in UCB compared to adult blood [103].
Therefore, UCB-derived ECFCs may play an important role in vascular and tissue regeneration. Since
the tissue healing process strongly depends on neovascularization, the use of this type of cell is
suggested for bone repair and regeneration.
Applications in BTE
EPCs are considered the link between angiogenesis and the development of native bone.
It has been shown that CD34+ cells/EPCs are able to differentiate into osteoblasts in vitro and
in vivo [260,261]. The healing potential of these cells is contributed by two mechanisms: (1) their
osteogenic and endothelial differentiation potential and (2) their paracrine effect (i.e., secreting VEGF)
(Figure 8) [262].
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The authors showed the formation of luminal tubular structures in the cell-containing scaffolds 
during the first seven days of the seeding. In addition, they observed the earlier osteogenic 
differentiation of MSCs in the co-cultured group in comparison to MSC monocultures, which 
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Due to improved angiogenesis, co-culturing EPCs with MSCs has been proposed for promoting
bone repair process. On this matter, Duttenhoefer et al. prepared an in vitro pre-vascularized 3D
construct made of polyurethane (PU) seeded by human EPCs (CD34+ and CD133+) and MSCs [263].
The authors showed the formation of luminal tubular structures in the cell-containing scaffolds during
the first seven days of the seeding. In addition, they observed the earlier osteogenic differentiation
of MSCs in the co-cultured group in comparison to MSC monocultures, which suggests the close
cooperation between the two cell populations.
3.4.3.4. Umbilical Cord Perivascular Cells (HUCPVCs)
General Information
The perivascular region of the human umbilical cord has been recently identified as a rich source
of adult MSCs. Human umbilical cord perivascular cells (HUCPVCs) are different from those isolated
from the bulk of Wharton’s Jelly. As stated by the International Society for Cell Therapy, these cells
contain a subpopulation that sh w the minimum criteria of mesenchymal stromal c s such as
multi-lineage differentiation capacity [264]. Like ADSCs, the prol f ati n rate of HUCPVCs is higher
than BM-MSCs with a significantly greater olony forming unit-fibroblast (CFU-F) frequency at harvest
equaling 1:300 [265]. Similar to other UC-derived MSCs, HUCPVCs may suppress immunoreactions in
hosts due to he lack of expression of class I and II major histocompatibility (MH ) antigens [265,266].
A simple method has been proposed by Ennis et al. for the isolation of HUCPVC from the UC. First,
three vessels with their surrounding tissue are i olated from the WJ matrix. Th n, both sides of the
isolated vessels are tied by a silk suture and t en placed into a 50 mL centrifuge ube containing a
diges ion solution (1 mg/mL collagenase in PBS) for 24 hours. Lastly, the vessels are removed from
the digestion m dium, and the resulting suspension was centrifuged. The resulting medium contains
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C rrently, th re is a relative paucity of reports on the potential of these cells to differentiate
into different lineages. Howe r, the multi-lineage differen iation HUCPVCs has be claimed
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by Zebardast et al. [264]. Furthermore, the therapeutic potential of HUCPVCs has been previously
reported for wound healing [268] and myocardial infarction [269]. In addition, there are some reports
of their application in bone regeneration strategies [270,271].
Applications in BTE
In 2013, Tsang et al. presented HUCPVCs as a reliable cell source for skeletal regeneration [272].
They isolated CD146+ HUCPVCs from the UC and then purified and enriched them using CD146
Magnetic MicroBeads. The multi-lineage differentiation capacity of this population was identified
under normoxic and hypoxic conditions in vitro. Moreover, the authors demonstrated in vivo
osteogenesis of HUCPVCs-Gelfoam-alginate 3D complexes via the implantation of them into a
critical-sized bone defect model in SCID mice. The in vitro results showed that the hypoxic conditions
can suppress the osteogenic differentiation but may increase cell proliferation and colony-forming
efficiency of the cells in comparison with that under normoxic conditions. The in vivo results confirmed
the active role of CD146+ HUCPVCs in the new bone formation and produced cartilaginous callus and
bony callus. According to these data, the authors stated that CD146+ HUCPVCs could be considered
a highly promising cell type for use in bone tissue regeneration. Gökçinar-Yagci in 2016 proved the
osteogenic capacity of HUCPVCs [273]. They cultured these cells in an osteogenic medium (DMEM-LG
containing 10−7 M dexamethasone, 0.2 mM ascorbic acid, and 10 mM glycerol 2-phosphate) for 21 days.
Regarding flow cytometry and immunofluorescent staining results, HUCPVCs expressed α-SMA,
MAP1B, and Tenascin-C, which confirmed that these cells are the ancestors of MSCs in the vascular
area. In addition, alizarin red staining revealed that the cells could give rise to osteogenic lineages.
Kajiyama et al. analyzed and employed HUCPVCs as a proper alternative of MSCs for BTE
strategies [271]. They investigated the in vitro differentiation of HUCPVCs cultured with bone marrow
conditioned medium (BM-CM) and evaluated their bone formation potency in vivo. They showed
that, although HUCPVCs express negligible levels of osteogenic genes as compared to BM-MSC,
they increase ALP after culturing in the osteogenic medium in the presence of CM from BM-MSC.
The implantation of HUCPVCs together with a collagen sponge scaffold into a rat calvarial osteotomy
defect resulted in enhanced in vivo bone formation.
3.4.4. Dental Stem/Progenitor Cells
3.4.4.1. General Information
Dental tissues are identified as a rich source of stem/progenitor cells, which can be used
for TE applications [274]. As previously documented [275], different dental stem/progenitor cells
have been characterized and isolated in the human dental tissue including dental pulp stem cells
(DPSCs) [276], stem cells from exfoliated deciduous teeth (SHED) [277], periodontal ligament stem
cells (PDLSCs) [278], stem cells from apical papilla (SCAP) [279], alveolar bone-derived mesenchymal
stem cells (ABMSCs) [280], gingiva-derived MSCs (GMSCs) [281], dental follicle stem/progenitor cells
(DFPCs) [282], and tooth germ progenitor cells (TGPCs) [283] (Figure 9). The MSCs of dental tissues
instead of progenitors exhibit the minimal characterization criteria for human stem cells well-defined
by the International Society for Cellular Therapy (ISCT) [162]. The differentiation of these cells into
various cell lineages including hepatocytes [284], osteogenic [285], and neurogenic cells [286] has
been confirmed.
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tooth germ progenitor cells. SCAP: stem cells from the apical papilla. OESCs: oral epithelial 
progenitor/stem cells. GMSCs: gingiva-derived MSCs. PSCs: periosteum-derived stem cells. SGSCs: 
salivary gland-derived stem cells with permission from Reference [287]. 
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immuno-cytofluorescence analyses. In terms of cellular functions, it has been demonstrated that the 
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Among these cells, DPSCs have been extensively studied for use in hard TE [288]. DPSCs were
initially isolated and characterized by Gronthos and his colleagues in 2000 [276]. They found that
these cells possess a high proliferation rate and a high level of clonogenicity with the ability to produce
densely calcified colonies and bone nodules [289]. DPSCs with these features are suitable candidates
for cell-based therapies in orthopedic, oral, and maxillofacial reconstruction [290].
SHED cells are other MSCs, which were first harvested and characterized by Miura et al.
from primary dentition systems. Like DPSCs, these cells are highly proliferative with the ability
to differentiate into different cell lines [291]. PDLSCs were recognized as the MSCs resident
in the perivascular space of the periodontium and can be obtained from mature periodontal
ligaments. Seo et al. in 2004 first isolated these cells from human impacted third molars [278].
Currently, a number of locations are used to isolate these cells including root surface (r-PDLSCs),
alveolar bone (a-PDLSCs) [240], deciduous teeth (d-PDLSCs) [292–294], and permanent teeth
(p-PDLSCs) [294]. Compared to the conventional PDLSCs, inflamed PDLSCs (i-PDLSCs) originate
from pathological conditions and possess a higher proliferation rate, as well as faster migration,
but have a lower osteogenic capacity [295]. Although PDLSCs are suitable cells for TE applications,
the big obstacle for using them in autologous transplantation is the inevitable tooth extraction [296].
Sonoyama et al. first introduced SCAPs as a population of stem cells located in the tooth root apex [297].
They showed the stemness characteristic of SCAPs by using histologic, immuno-histochemical,
and immuno-cytofluorescence analyses. In terms of cellular functions, it has been demonstrated
that the proliferation rate and plasticity of SCAPs are greater than DPSCs in vitro, which makes
them a suitable source for cell-based therapies [298]. The first report on the successful isolation
of ABMSCs belongs to Matsubara et al. [280]. This type of cell is similar to other dental-derived
MSCs with reference to biological properties such as morphology, which is the ability to adhere
to plastic and colony formation [274]. GMSCs are a new population of stem cells obtained from
human gingival tissue. Like other MSCs, these cells are capable of clonogenicity, self-renewal, and
multipotent differentiation. The GMSCs can be easily isolated from the oral cavity of human or
animals via gingivectomy techniques with minimal discomfort [299]. Under an appropriate cell culture
medium, these cells may differentiate into cells of all embryo layers [300]. The therapeutic potential
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of GMSCs for skin wound healing [301], bone [302], and tendon [303] regeneration have been well
documented. Using a dental follicle as an ectomesenchymal tissue contains a population of progenitor
cells (i.e., DFPCs) that are responsible for the formation of the periodontium. These cells are usually
isolated using enzymatic digestion from human impacted third molars. Like other dental stem cells,
DFPCs form low numbers of adherent and clonogenic cells in the culture condition [304]. These cells
are more undifferentiated than DPSCs and show the main properties of MSCs such as differentiation
into osteogenic [305] and neuronal cell lines [306]. As a novel stem cell population, TGPCs was first
identified and named by Ikeda et al. [283]. These cells, which are located in the dental mesenchyme of
the third molar tooth, germ during the late bell stage [307]. It has been shown that TGPCs are able to
differentiate into cells of three germ layers (osteoblasts, neural cells, and hepatocytes) [287]. Therefore,
they are suitable cells for TE applications including bone regeneration.
3.4.4.2. Applications in BTE
The use of DPSCs for BTE applications has been widely investigated in recent years. These cells
express osteogenic commitment markers (e.g., BGLAP, Osx, and OP) and can produce bone-like nodule
formation in vitro [308]. As recently reviewed by Cristaldi et al., DPSCs are a valuable cell source
for bone repair and regeneration strategies when they are applied together with suitable natural and
synthetic scaffolds [309]. For example, d’Aquino et al. grafted DPSCs with collagen sponge complexes
in order to regenerate human mandible bone defect [310]. The results revealed that the alveolar
bone had optimal vertical repair and complete restoration of periodontal tissue after three months of
grafting. In addition, histological observations demonstrated the complete regeneration of bone at the
injury site at one-year post-grafting. More studies have focused on the use of these cells with synthetic
scaffolds, especially those made of tricalcium phosphate [311,312].
The in vitro and in vivo osteogenic differentiations of SHEDs were also identified in various
experimental studies [313–315]. A high proliferation rate and a less invasive procedure for obtaining
SHEDs are considered beneficial in comparison with BM-MSCs. Moreover, it has been reported
that SHEDs have a higher proliferation rate and differentiation ability in vitro, as well as a higher
mineralization potential in vivo compared to the DPSCs [291]. However, there are other studies
reporting a lack of significant differences among the cells mentioned above regarding bone regeneration
capacity. As an illustration, Nakajima et al. compared the bone regeneration ability among human
SHEDs, DPSCs, and BM-MSCs in vivo [316]. The authors transplanted all three types of stem cells
with a poly(lactic-co-glycolic acid) (PLGA) barrier membrane as a scaffold for reconstruction of a
critical-sized bone defect in the calvaria of immuno-deficient mice. The results showed that there
was no significant difference among different groups in terms of bone regeneration after 12 weeks
of implantation. However, the largest osteoid and widely distributed collagen fibers were observed
in the animals treated with SHEDs/scaffolds as compared to other groups. The authors concluded
that SHEDs could be used as one of the best cell sources for the reconstruction of the alveolar cleft.
However, there are some disadvantages regarding the use of SHEDs in BTE applications such as the
need to extract healthy teeth in order to isolate and harvest the MSCs.
As another stem cell source in the teeth, PDLSCs can give rise to the osteogenic lineages in vitro
and in vivo. In 2010, Chadipiralla et al. compared the in vitro osteogenesis potential between PDLSCs
and SHEDs [317]. The authors cultured both cell types in a medium containing retinoic acid (RA)
and dexamethasone (Dex) for 21 days. Their results revealed that RA and Dex have inhibitory effects
on the proliferation of SHEDs and PDLSCs. However, RA could significantly up-regulate the gene
expression of osteogenic markers like ALP in both cell types. This effect was increased after adding
insulin to the culture medium. Although, RA+ insulin treatment had better effects on the proliferation
of PDLSCs and, thereby, led to greater calcium deposition at three weeks post-incubation. The
authors concluded that PDLSCs are a better osteogenic stem cell source than SHEDs. This ability
along with the immunomodulatory properties offers PDLSCs as good alternatives to BM-MSCs in
BTE applications [318,319]. Similar to other cells, the genetic engineering of this type of stem cell
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via the insertion and subsequent up-regulation of genes involved in osteogenesis (e.g., BMP2) may
improve their potency in terms of in vivo bone reconstruction [320,321]. Yu et al. in 2014 compared the
potential of PDLSCs versus BM-MSCs in combination with Bio-Oss® commercial scaffolds for ectopic
and in situ bone formation [322]. They subcutaneously implanted the cell-containing constructs in
critical-size defects in the immuno-deficient rat calvarium. The results of micro-computed tomography
(µ-CT), histology, histo-morphometry, and immuno-histochemistry showed that the PDLSC/Bio-Oss®
construct is superior to the BMMSC/Bio-Oss® construct regarding bone healing of critically-sized
defects in rats.
The potential of ABMSCs to differentiate osteoblasts has been previously investigated under
various conditions [323]. However, there are few reports on both in vitro and in vivo osteo-genesis
of this type of stem cells. In 2012, Kim et al. evaluated the growth and osteogenic differentiation
of ABMSCs on chitosan/hydroxyapatite (CS/HAp) composites [324]. The authors showed that the
composites could support the proliferation and attachment of ABMSCs. In addition, the results of
ALP staining and gene expression showed that the composites could improve the osteogenic capacity
of ABMSCs more than the CS constructs. The in vivo bone regeneration ability of these cells with
different carriers has also been evaluated by Park et al. [325]. In that study, the authors used biphasic
HAp/TCP particles or commercial Bio-Oss® for cell delivery in a murine ectopic transplantation
model. The results showed that both carriers could support the cell attachment. Moreover, a significant
newly formed bone tissue was histologically observed in the HAp/TCP groups, while the amounts
were lower on the Bio-Oss® group. The authors concluded that both types of constructs had a high
stem cell-carrying potential. However, the in vivo bone healing process revealed that the osteogenic
capacity of hABMSC is affected by the microenvironment on the surfaces of the scaffolds.
GMSCs were found to be superior to BM-MSCs for cell therapy in regenerative medicine
strategies [326]. Tomar et al. summarized the following reasons for their claim: (1) ease isolation,
(2) homogeneity and fast proliferation, (3) stable morphology at higher passages, (4) maintaining
the normal karyotype and telomerase activity in long-term cultures, and (5) lack of tumorigenicity.
Moreover, Zhang et al. reported another merit for these cells known as immunomodulatory functions.
Specifically, they can suppress peripheral blood lymphocyte proliferation as well as induce the
expression of a broad range of immunosuppressive factors (e.g., IL-10, iNOS, and COX-2) in response
to the inflammatory cytokine IFN-γ [281]. The osteogenic potential of GMSCs has been previously
evaluated and compared to PDLSCs [327]. The obtained results showed that PDLSCs are more effective
in terms of osteogenic differentiation as compared to GMSCs. In addition, GMSCs showed fewer
inflammation-related changes regarding osteogenic potential in vitro and bone formation in vivo in
comparison with PDLSCs. For the functional evaluation of GMSCs for bone regeneration, Wang et al.
applied GMSCs with type I collagen in order to fill mandibular and calvarial defects prepared in
rats [302]. The histological analyses demonstrated that the cell-containing constructs could repair the
mandibular and calvarial defects after two months of surgery. The authors stated that GMSCs could be
considered a novel stem cell source with the ability to use bone reconstruction in clinical applications.
The capacity of DFPCs regarding inducing calcification had been previously documented in vitro
and in vivo [328,329]. Therefore, it is possible to use this type of cell for bone repair and regeneration
strategies. However, there are very few studies regarding the potential of this type of stem cells for
BTE strategies.
3.4.5. Periosteum-Derived Progenitor Cells (PDPCs)
3.4.5.1. General Information
The periosteum is a thin fibrous membrane that covers the outer surface of most bones. This
membrane is divided into an outer fibrous layer containing elastic fibers as well as micro-vessels
and an inner osteogenic layer containing periosteum-derived progenitor cells (PDPCs). Although
the osteogenic potential of periosteum as a whole has been reported in the 1800s [330], determining
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periosteum as the main source of PDPCs was documented in 2009 [331]. PDPCs have multi-potential
capacity and possess an important role in bone development and fracture healing. After any fracture,
these cells are capable of differentiating into osteoblasts and are able to improve a bone repair process.
In contrast to other MSCs, PDPCs obtained from the elderly have performances comparable to those
isolated from younger people [332,333]. The reason this was proposed for this event is related to
the stability of their telomeres in vitro. Several different protocols have been applied to dissect
the periosteum and, thereby, isolate PDPCs from humans. As previously mentioned, one of the
best methods proposed is removing the periosteum by a periosteum elevator or similar surgical
instrument [334]. As an important point, the integrity of the periosteum tissue is maintained by this
method and also damage to the underlying bone is minimized [335]. The isolation of cells from the
dissected periosteum is typically carried out by enzymatic digestion or cell regression. In a cultured
condition, PDPCs exhibit a high proliferation rate that results in their shortened culture time and,
thereby, in the reduction of the cost and the risk of microbial contaminations [336].
3.4.5.2. Applications in BTE
PDPCs have been proposed as suitable alternatives for BTE applications due to their supreme
characteristics such as a high proliferation rate, easy isolation, and expansion as well as the high
potential of differentiation into osteogenic lineages [330]. Moreover, it has been shown that PDPCs
have greater in vitro osteogenic potential in comparison to MSCs derived from other sources such as
adipose tissue or synovium [337]. As previously clarified in the literature, the osteogenic potential of
PDPCs is affected by a series of items including the harvesting site, donor conditions, and technical
factors. As an illustration, the PDPCs derived from load-bearing bones possess a more osteogenic
capacity than those that originated from flat bones [338–340].
In 2006, Yi-Xiong et al. evaluated the osteogenic potential of human PDPCs in 3D PLGA
scaffolds using allogeneic serum [341]. They seeded the expanded cells onto the 3D PLGA constructs
and cultured them in an osteogenic medium for 28 days. The authors examined the ossification
process using molecular and histopathological analyses. The newly formed bone-like nodules and
over-expression of osteogenic genes (collagen I, osteocalcin, and osteonectin) were observed, which
confirm the potential of this system for the creation of new bone in vivo.
3.4.6. Synovium-Derived Mesenchymal Stem Cells
3.4.6.1. General Information
The synovial membrane (synovium) is a specialized soft connective tissue that lines the inner
surface of the cavities of joints, tendon sheaths, and bursae. The ability of synovium to heal itself
after subtotal surgical synovectomy is considered a noteworthy sign indicating its high regenerative
potential [342]. In this regard, De Bari et al. published the first report for the presence of a
subpopulation of MSCs in human synovium (S-MSCs) in 2001 [343]. Since then, synovium has
been identified as a promising source of MSCs for therapeutic applications such as musculoskeletal
regeneration [344].
Under proper environmental cues, these cells exhibit common features of MSCs such as
differentiation into cell lineages such as myocytes, adipocytes, chondrocytes, and osteocytes
in vitro [343]. In addition to humans, these cells have also been isolated from other species such
as rats [345]. The isolation procedure of S-MSCs consists of a simple protocol in which harvested
fresh synovial tissue is shattered to pieces (by shears) and then is digested using a collagenase
solution of suitable concentration (Figure 10) [343,346]. It has been previously proposed that
S-MSCs have similar characteristics in comparison to BMSCs including the morphology, immune
phenotype, colony frequency, and differentiation capacity [347,348]. However, there is some evidence
showing that S-MSCs have a higher colony-forming efficiency and proliferation rate in comparison to
BM-MSCS [347].
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It has been previously shown that S-MSCs are good candidates for cartilage reconstruction
since they express the hyaluronan receptor (CD44) and uridine diphosphoglucose dehydrogenase
(UDPGD), which is a vital enzyme for hyaluronan synthesis [350]. Although in vitro cultured S-MSCs
specifically tend to differentiate into chondrocytes, new attempts have been made to utilize them for
bone regeneration strategies.
3.4.6.2. Applications in BTE
There are few reports in the literature demonstrating that S-MSCs can differentiate into osteogenic
lineages under the specific osteogenic medium in vitro [343,345,351]. It has been shown that these
cells have a greater osteogenic capacity in comparison to ASCs and muscle-derived stem cells
(MD-SCs) [346]. However, the osteogenic potential of S-MSCs is much less than BM-MSCs when
cultured in similar osteogenic medium [347]. Additionally, De Bari et al. reported that S-MSCs are
inferior in osteogenic capability as compared to PDPCs [352]. The implantation of S-MSCs together
with hydroxyapatite (HAp) as cell-matrix composites has been evaluated for bone repair [353]. After
being implanted, the cell-containing constructs could accelerate in vivo osteo-induction as compared
to the constructs without cells. In another study, Lee et al. tried to repair osteo-chondral defects using
an S-MSCs-encapsulated injectable gel (type I collagen/hyaluronic acid/fibrinogen (COL/HA/FG)).
Their results revealed the effectiveness of this system for improving osteo-chondral defects in rabbits.
3.4.7. Muscle-Derived Stem Cells (MD-SCs)
3.4.7.1. General Information
Human skeletal muscle has been recently recognized as a valid source of progenitor or stem
cells. This tissue contains two distinct stem cells including satellite cells (myogenic precursors) and
muscle-derived stem cells (MDSCs), which are primarily responsible for muscle regeneration [354].
Although satellite cells exhibit multi-potentiality and self-renewal capabilities, they are committed
to the myogenic lineage. They are located under the basal lamina of mature skeletal muscle fibers.
Compared to the satellite cells, the MDSCs are considered stem cells, which are not restricted to
the myogenic lineage and can differentiate into multiple lineages. Currently, these cells are named
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mesenchymal stem cells due to their ability to differentiate into the mesodermal phenotypes as well as
to express MSCs’ specific markers such as CD73, CD90, CD105, and CD44 [355].
Even though stem cells derived from bone marrow and adipose tissue are considered two of the
most useful cells for clinical application, they suffer from the lack of continuous availability and less
efficiency for bone regeneration after freezing, respectively. Therefore, the human muscle-derived cells
are proposed as an alternative stem cell source, which is able to differentiate in vitro and form bone
and cartilage tissues in vivo without being affected by the previously mentioned limitations [356,357].
MDSCs secrete trophic factors that may stimulate and regulate endogenous mechanisms of tissue
regeneration [358]. Having these properties, MDSCs are used in different tissue engineering strategies
to accelerate the regeneration of damaged tissues. The isolation of the MDSCs consists of a minimally
invasive procedure known as a needle biopsy of various muscles [359].
3.4.7.2. Applications in BTE
The usability of MDSCs for bone repair and regeneration has been shown in several studies [360,361].
As an interesting point, Corsi et al. showed that donor sex has a great influence on the osteogenic
potential of MDSCs [362]. They stimulated both human male-derived and female-derived cells by BMP4
in order to provide an osteogenic condition. With respect to the in vitro results, the authors stated that
male MDSCs (M-MDSCs) are more potent cells than female ones (F-MDSCs) regarding bone healing
strategies. Moreover, the in vivo results showed that BMP4-induced M-MDSCs could form a more
consistent and denser ectopic bone as compared to BMP4-induced F-MDSCs. The authors claimed that
the greater osteogenic potential of M-MDSCs is likely related to the higher number of osteo-progenitor
cells within them.
The in vivo osteogenic differentiation of rat MDSCs (rMDSCs) has been examined within an
injectable in situ-forming chitosan scaffolds [363]. For this aim, the isolated cells were seeded onto the
scaffolds and then implanted in the subcutaneous dorsum of a rat as follows: G1 (0.5 mL chitosan gel),
G2 (0.5 mL chitosan gel + 0.1 mL osteogenic factor solution), G3 (0.5 mL gel + 5 × 105 rMDSCs), and G4
(0.5 mL gel + 5 × 105 rMDSCs + 0.1 mL osteogenic factor solution). The in vitro results showed that
chitosan is a suitable substance for cell attachment and proliferation. The newly formed bone was only
observed in the animals receiving the chitosan gel containing both rMDSCs and osteogenic factors.
Furthermore, adding cells to the chitosan gels resulted in lower host tissue responses as compared to
the chitosan gel alone, which clarifies the immunosuppression activity of the transplanted rMDSCs.
In 2014, Gao et al. compared the osteogenic potential of human MDSCs and BM-MSCs in vitro and
in vivo [355]. Their results showed that both cell types have an equal in vitro osteogenic differentiation
potential after being transduced to express BMP2. In addition, the in vivo results showed that fibrin
sealant scaffolds containing the transduced cells could regenerate new bone in the critically-sized
calvarial defects in mice. No significant differences were reported regarding the newly formed
bone volumes and bone defect coverage between the MDSCs and BM-MSC groups. Quicker bone
remodeling was observed in the animals treated with the scaffolds contacting BMP2-transduced
MDSCs. The authors concluded that MDSCs could be considered as efficient alternatives to BMMSCs
in terms of bone repair and regeneration.
4. The Future—Where Are We Going?
Twenty years have passed since the first implantation of a cell-seeded porous biomaterial
was performed in a bone segmental defect of a human patient. In a paper published in 2001,
Quarto et al. [364] reported the successful repair of large bone defects (4–8 cm) via custom-made
porous hydroxyapatite scaffolds seeded with autologous BM-MSCs. Specifically, four patients were
recruited in 1998 for this study after unsuccessful treatment by conventional orthopedic surgery. All
patients recovered limb function within six to 12 months and, over a 6.5-year follow-up, none of
them experienced major complications or reported significant complaints. No late fractures in the
implant zones were observed [365]. This work was one of the milestones that paved the way for
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modern bone regenerative medicine. In addition, in 2001, a second fundamental report was published
by Vacanti et al. [366] who replaced an osseous defect in the distal phalanx of a patient’s thumb,
which was caused by an avulsion injury through the implantation of a coralline porous implant
seeded with PDPCs that were previously expanded in vitro. At that time, this publication raised some
debate in the scientific community given the availability of simpler options (from both technical and
economic viewpoints), which could be selected to solve this specific clinical problem. Commenting
on this article in the Editorial to the journal issue, Hentz and Chang wrote that “although some
specialists in reconstructive hand surgery might consider this technique an unnecessarily complex and
time-consuming approach to a simple clinical problem,” this approach is “an important effort to bring
tissue engineering to the fields of hand surgery and reconstructive surgery” [367].
Following these pioneering achievements, tremendous advancements have been carried out over
the last two decades for the selection and isolations of suitable cell types for bone tissue engineering
strategies, which has been reviewed in the present paper. A key goal of many studies has been
to try overcoming the objections highlighted by Hentz and Chang in 2001, i.e., the technical and
economic burdens associated with cell-based tissue engineering strategies. In this regard, translation
“from bench to bed” may be particularly difficult and draining. In fact, the combination of high
innovation—which is not always positively accepted by the market and clinicians–, high complexity
and high production/certification costs are the main critical issues to be overcome for a wide diffusion
of cell-based tissue-engineered constructs. As critically discussed by Fernandez-Moure in a valuable
paper [368], the deepest “valley of death” where new technologies and products may be lost while
moving from the bench to the bedside, is the technological transfer from lab-scale (academia and
research centers) to industries and clinical implementation.
The dream of all clinicians is to have an off-the-shelf cell-based product that is free from the typical
drawbacks of tissue transplants (i.e., limited availability, need for additional surgery, and the risk of
disease transmission) and is readily available to be used for bone regeneration in all patients [369].
BTE has the potential to meet this complex challenge and become a feasible alternative to tissue
transplantation, provided that a strategy for homogenously supplying oxygen and nutrients to the
cells in the inner part of the implanted scaffold is developed [370].
Currently, various cells have been applied (alone or in combination with biomaterials) to accelerate
bone repair in vivo with sophisticated outputs. However, the main critical question remains ‘which
cell source is the best for using in BTE strategies?’ The answer to this query is not clear since there are
pros and cons for each cell type. In general, several factors dictate the selection criteria of cells such as
ease and cost of treatment as well as availability. As compared to autogenic cells, the allogenic sources
are considered to be more available cells with fewer problems in terms of developing commercial
products [371].
The use of ESCs offer an unlimited supply of cells with the ability to differentiate into the
osteogenic lineage. However, there are some specific barriers that prevent their widespread use
including ethical issues and tumorigenicity risk. The development of iPSCs is the intelligent way
to have the advantages as well as remove the disadvantages of ESCs. After being introduced by
Professor Shinya Yamanaka, more attention has been paid to use hiPSc for repair of bone diseases
and damages [372]. Some studies clarified that these cells are comparable in vivo bone regeneration
and angiogenic capability to hBMSCs and hUCMSCs on rats [373]. However, no clinical trials have
been conducted using these cells for bone-related disorders. As an optimal cell source for BTE, MSCs
derived from different origins (bone marrow and adipose) have been used for BTE applications
more than other cell types. These cells through the secretion of various therapeutic factors show
an excellent ability to accelerate bone healing [374]. It is worth noting that the term of ‘Medicinal
Signaling Cell’ is recently proposed by Professor Arnold I. Kaplan instead of ‘Mesenchymal stem
cell’ [375]. He believes that “these cells do not function in the body as progenitors for tissues, neither
in the normal steady-state nor in disease or injury circumstances. They are not stem cells.” The
reason for this newly suggested term is related to the secretion of bioactive molecules as therapeutic
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drugs from MSCs to the micro-environment providing an in situ medicinal condition for the patient’s
own site-specific and tissue-specific resident stem cells that construct the new tissue. These bioactive
molecules are comprised of various growth factors, cytokines, and chemokines that exert anti-apoptotic,
immunomodulatory, anti-scarring, supportive, angiogenic, and chemoattractant effects (Figure 11).
From the regeneration point of view, there are differences among various stem cells derived from
mesenchymal tissues. For example, it has been reported that BM-MSCs have higher osteogenic
potential as compared to ASCs and UC-MSCs in a rat’s calvarial defect [169]. However, the isolation
and culturing procedures of BM-MSCs are time-consuming and overwhelming processes.
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In conclusion, the final aim of each experimental study may provide the proof for using each cell
type for a BTE application. Taking advantage of previously reported studies can be helpful for the
researcher to select appropriate cell sources for their work, either animal or human trials. Historically,
MSCs could be beneficial for accelerating the bone repair and regeneration. However, recent studies
focus on the use of iPSCs as a reliable cell source for bone reconstruction. Nonetheless, it is too early
to draw definite conclusions about the success of these cells, and additional clinical trials need to
be conducted.
A dramatic revolution has also recently arisen in the genome editing of human pluripotent stem
cells (hPSC) with the advent of novel technologies like zinc finger nucleases (ZFNs), transcription
activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic
repeats (CRISPR)-Cas9-nucleases. These technologies represent powerful tools to generate various
cell types for targeted therapies and clinical transplantation. As a final point, the role of
biomaterials includes the healing ability of cells when they are used simultaneously. In this regard,
three-dimensional (3D) bio-printing as a cutting-edge technology could open up new horizons to
clinicians for better utilization of cell-biomaterial constructs in the treatment of tissue injuries like bone
damages. Accordingly, the understanding of the interactions between cells and different biomaterials
is strongly suggested to get better results.
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